TABLE 4.

Antimicrobial susceptibility profiles for MSSA and MRSA isolates

Antimicrobial agentNo. of susceptible isolates (%) among:
MSSA in:MRSA in:
2001 to 2002 (n = 316)2003 to 2004 (n = 237)2001 to 2002 (n = 75)2003 to 2004 (n = 134)
Chloramphenicol273 (86.4)197 (83.1)49 (65.3)69 (51.9)
Clindamycina316 (100)232 (97.9)51 (68.0)88 (66.4)
Clindamycinb263 (83.2)184 (77.6)34 (45.0)50 (37.6)
Erythromycin250 (79.1)180 (76.0)19 (25.3)24 (18.1)
Gentamicin315 (99.7)236 (99.6)75 (100)12 (99.3)
Levofloxacin315 (99.7)233 (98.3)34 (45.3)60 (45.1)
Linezolid316 (100)237 (100)75 (100)133 (100)
Penicillin39 (12.3)27 (11.4)0 (0)0 (0)
Oxacillin316 (100)237 (100)0 (0)0 (0)
Quinupristin-Dalfopristin301 (100)237 (100)75 (100)133 (100)
Rifampin316 (100)237 (100)74 (98.7)131 (98.5)
Tetracycline306 (96.8)230 (97.0)69 (92.0)122 (91.7)
Trimethoprim- sulfamethoxazole316 (100)235 (99.2)75 (100)133 (100)
Vancomycin316 (100)237 (100)75 (100)133 (100)
  • a Decrease in susceptibility due to constitutive resistance only.

  • b Decrease in susceptibility due to inducible and constitutive resistance.